Patents by Inventor Wayne C. Widdison

Wayne C. Widdison has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS FOR THE ACYLATION OF MAYTANSINOL
    Publication number: 20240145953
    Abstract: Disclosed is a method of preparing an amino acid ester of maytansinol by reacting maytansinol with an N-carboxyanhydride of an amino acid (NCA) in the presence of a drying agent. Also disclosed is an improved method of preparing an amino acid ester of maytansinol in which a nucleophile is added to the reaction mixture after completion of the reaction between maytansinol and an N-carboxyanhydride of an amino acid.
    Type: Application
    Filed: September 5, 2023
    Publication date: May 2, 2024
    Inventors: Wayne C. Widdison, Robert Yongxin Zhao
  • CAMPTOTHECIN DERIVATIVES
    Publication number: 20220133711
    Abstract: Disclosed herein are novel cytotoxic compounds, and cytotoxic conjugates comprising these cytotoxic compounds and cell-binding agents. More specifically, this disclosure relates to novel camptothecin derivatives thereof, intermediates thereof, conjugates thereof, and pharmaceutically acceptable salts thereof, which are useful as medicaments, in particular as anti-proliferative agents (anticancer agents).
    Type: Application
    Filed: October 15, 2021
    Publication date: May 5, 2022
    Inventors: Ravi V.J. Chari, Wayne C. Widdison, Wei Li, David P. Pleynet
  • MAYTANSINOID DERIVATIVES WITH SELF-IMMOLATIVE PEPTIDE LINKERS AND CONJUGATES THEREOF
    Publication number: 20220111067
    Abstract: The invention relates to novel cell-binding agent-maytansinoid conjugate having a self-immolative peptide linker and more specifically to conjugates of formula (I). The invention also provides novel maytansinoid compounds of formula (II), (III), (IV) or (V). The invention further provides compositions and methods useful for inhibiting abnormal cell growth or treating a proliferative disorder in a mammal using the compounds or conjugates of the invention.
    Type: Application
    Filed: August 19, 2021
    Publication date: April 14, 2022
    Inventor: Wayne C. Widdison
  • Camptothecin derivatives
    Patent number: 11229639
    Abstract: Disclosed herein are novel cytotoxic compounds, and cytotoxic conjugates comprising these cytotoxic compounds and cell-binding agents. More specifically, this disclosure relates to novel camptothecin derivatives thereof, intermediates thereof, conjugates thereof, and pharmaceutically acceptable salts thereof, which are useful as medicaments, in particular as anti-proliferative agents (anticancer agents).
    Type: Grant
    Filed: September 25, 2020
    Date of Patent: January 25, 2022
    Assignee: IMMUNOGEN, INC.
    Inventors: Ravi V. J. Chari, Wayne C. Widdison, Wei Li, David P. Pleynet
  • Maytansinoid derivatives with self-immolative peptide linkers and conjugates thereof
    Patent number: 11135308
    Abstract: The invention relates to novel cell-binding agent-maytansinoid conjugate having a self-immolative peptide linker and more specifically to conjugates of formula (I). The invention also provides novel maytansinoid compounds of formula (II), (III), (IV) or (V). The invention further provides compositions and methods useful for inhibiting abnormal cell growth or treating a proliferative disorder in a mammal using the compounds or conjugates of the invention.
    Type: Grant
    Filed: November 22, 2019
    Date of Patent: October 5, 2021
    Assignee: IMMUNOGEN, INC.
    Inventor: Wayne C. Widdison
  • Cross-linkers and their uses
    Patent number: 11046762
    Abstract: Charged or pro-charged cross-linking moieties and conjugates of cell binding agents and drugs comprising the charged or pro-charged cross-linking moieties and method of making the same.
    Type: Grant
    Filed: October 14, 2019
    Date of Patent: June 29, 2021
    Assignee: IMMUNOGEN, INC.
    Inventors: Ravi V. J. Chari, Robert Yongxin Zhao, Yelena Kovtun, Rajeeva Singh, Wayne C. Widdison
  • CAMPTOTHECIN DERIVATIVES
    Publication number: 20210077482
    Abstract: Disclosed herein are novel cytotoxic compounds, and cytotoxic conjugates comprising these cytotoxic compounds and cell-binding agents. More specifically, this disclosure relates to novel camptothecin derivatives thereof, intermediates thereof, conjugates thereof, and pharmaceutically acceptable salts thereof, which are useful as medicaments, in particular as anti-proliferative agents (anticancer agents).
    Type: Application
    Filed: September 25, 2020
    Publication date: March 18, 2021
    Inventors: Ravi V.J. Chari, Wayne C. Widdison, Wei Li, David P. Pleynet
  • Methods for the acylation of maytansinol
    Patent number: 10944190
    Abstract: Disclosed is a method of preparing an amino acid ester of maytansinol by reacting maytansinol with an N-carboxyanhydride of an amino acid (NCA) in the presence of a drying agent. Also disclosed is an improved method of preparing an amino acid ester of maytansinol in which a nucleophile is added to the reaction mixture after completion of the reaction between maytansinol and an N-carboxyanhydride of an amino acid.
    Type: Grant
    Filed: September 18, 2019
    Date of Patent: March 9, 2021
    Assignee: IMMUNOGEN, INC.
    Inventors: Wayne C. Widdison, Robert Yongxin Zhao
  • Maytansinoid derivatives with self-immolative peptide linkers and conjugates thereof
    Patent number: 10792372
    Abstract: The invention relates to novel cell-binding agent-maytansinoid conjugate having a self-immolative peptide linker and more specifically to conjugates of formula (I). The invention also provides novel maytansinoid compounds of formula (II), (III), (IV) or (V). The invention further provides compositions and methods useful for inhibiting abnormal cell growth or treating a proliferative disorder in a mammal using the compounds or conjugates of the invention.
    Type: Grant
    Filed: February 27, 2018
    Date of Patent: October 6, 2020
    Assignee: IMMUNOGEN, INC.
    Inventor: Wayne C. Widdison
  • MAYTANSINOID DERIVATIVES WITH SELF-IMMOLATIVE PEPTIDE LINKERS AND CONJUGATES THEREOF
    Publication number: 20200197531
    Abstract: The invention relates to novel cell-binding agent-maytansinoid conjugate having a self-immolative peptide linker and more specifically to conjugates of formula (I). The invention also provides novel maytansinoid compounds of formula (II), (III), (IV) or (V). The invention further provides compositions and methods useful for inhibiting abnormal cell growth or treating a proliferative disorder in a mammal using the compounds or conjugates of the invention.
    Type: Application
    Filed: November 22, 2019
    Publication date: June 25, 2020
    Inventor: Wayne C. Widdison
  • METHODS FOR THE ACYLATION OF MAYTANSINOL
    Publication number: 20200153130
    Abstract: Disclosed is a method of preparing an amino acid ester of maytansinol by reacting maytansinol with an N-carboxyanhydride of an amino acid (NCA) in the presence of a drying agent. Also disclosed is an improved method of preparing an amino acid ester of maytansinol in which a nucleophile is added to the reaction mixture after completion of the reaction between maytansinol and an N-carboxyanhydride of an amino acid.
    Type: Application
    Filed: September 18, 2019
    Publication date: May 14, 2020
    Inventors: Wayne C. Widdison, Robert Yongxin Zhao
  • CROSS-LINKERS AND THEIR USES
    Publication number: 20200148764
    Abstract: Charged or pro-charged cross-linking moieties and conjugates of cell binding agents and drugs comprising the charged or pro-charged cross-linking moieties and method of making the same.
    Type: Application
    Filed: October 14, 2019
    Publication date: May 14, 2020
    Inventors: Ravi V.J. Chari, Robert Yongxin Zhao, Yelena Kovtun, Rajeeva Singh, Wayne C. Widdison
  • Maytansinoid derivatives with peptide linker and conjugates thereof
    Patent number: 10494423
    Abstract: The invention relates to novel cell-binding agent-cytotoxic agent conjugate having a peptide linkers and more specifically to conjugates of formula (I). The invention also provides novel cytotoxic agents of formula (II), linker compounds represented by formula (III), and drug-linker compounds represented by formula (IV). The invention further provides compositions and methods useful for inhibiting abnormal cell growth or treating a proliferative disorder in a mammal using the compounds or conjugates of the invention.
    Type: Grant
    Filed: February 9, 2016
    Date of Patent: December 3, 2019
    Assignee: IMMUNOGEN, INC.
    Inventor: Wayne C. Widdison
  • Cross-linkers and their uses
    Patent number: 10494431
    Abstract: Charged or pro-charged cross-linking moieties and conjugates of cell binding agents and drugs comprising the charged or pro-charged cross-linking moieties and method of making the same.
    Type: Grant
    Filed: March 5, 2018
    Date of Patent: December 3, 2019
    Assignee: IMMUNOGEN, INC.
    Inventors: Ravi V. J. Chari, Robert Yongxin Zhao, Yelena Kovtun, Rajeeva Singh, Wayne C. Widdison
  • Methods for the acylation of maytansinol
    Patent number: 10461449
    Abstract: Disclosed is a method of preparing an amino acid ester of maytansinol by reacting maytansinol with an N-carboxyanhydride of an amino acid (NCA) in the presence of a drying agent. Also disclosed is an improved method of preparing an amino acid ester of maytansinol in which a nucleophile is added to the reaction mixture after completion of the reaction between maytansinol and an N-carboxyanhydride of an amino acid.
    Type: Grant
    Filed: September 12, 2018
    Date of Patent: October 29, 2019
    Assignee: IMMUNOGEN, INC.
    Inventors: Wayne C. Widdison, Robert Yongxin Zhao
  • METHODS FOR THE ACYLATION OF MAYTANSINOL
    Publication number: 20190013604
    Abstract: Disclosed is a method of preparing an amino acid ester of maytansinol by reacting maytansinol with an N-carboxyanhydride of an amino acid (NCA) in the presence of a drying agent. Also disclosed is an improved method of preparing an amino acid ester of maytansinol in which a nucleophile is added to the reaction mixture after completion of the reaction between maytansinol and an N-carboxyanhydride of an amino acid.
    Type: Application
    Filed: September 12, 2018
    Publication date: January 10, 2019
    Inventors: Wayne C. Widdison, Robert Yongxin Zhao
  • MAYTANSINOID DERIVATIVES WITH SELF-IMMOLATIVE PEPTIDE LINKERS AND CONJUGATES THEREOF
    Publication number: 20180296694
    Abstract: The invention relates to novel cell-binding agent-maytansinoid conjugate having a self-immolative peptide linker and more specifically to conjugates of formula (I). The invention also provides novel maytansinoid compounds of formula (II), (III), (IV) or (V). The invention further provides compositions and methods useful for inhibiting abnormal cell growth or treating a proliferative disorder in a mammal using the compounds or conjugates of the invention.
    Type: Application
    Filed: February 27, 2018
    Publication date: October 18, 2018
    Inventor: Wayne C. Widdison
  • Methods for the acylation of maytansinol
    Patent number: 10100062
    Abstract: Disclosed is a method of preparing an amino acid ester of maytansinol by reacting maytansinol with an N-carboxyanhydride of an amino acid (NCA) in the presence of a drying agent. Also disclosed is an improved method of preparing an amino acid ester of maytansinol in which a nucleophile is added to the reaction mixture after completion of the reaction between maytansinol and an N-carboxyanhydride of an amino acid.
    Type: Grant
    Filed: September 19, 2017
    Date of Patent: October 16, 2018
    Assignee: IMMUNOGEN, INC.
    Inventors: Wayne C. Widdison, Robert Yongxin Zhao
  • CROSS-LINKERS AND THEIR USES
    Publication number: 20180291100
    Abstract: Charged or pro-charged cross-linking moieties and conjugates of cell binding agents and drugs comprising the charged or pro-charged cross-linking moieties and method of making the same.
    Type: Application
    Filed: March 5, 2018
    Publication date: October 11, 2018
    Inventors: Ravi V.J. Chari, Robert Yongxin Zhao, Yelena Kovtun, Rajeeva Singh, Wayne C. Widdison
  • Conjugates comprising cell-binding agents and maytansinoids as cytotoxic agents
    Patent number: 9999680
    Abstract: The invention provides linker compounds containing a disulfide group, and maytansin-derived cytotoxic compounds that are useful for forming a CBA-drug conjugates, and conjugates so formed. Such conjugates and/or cytotoxic compounds may be effective for treating a range of diseases, such as cancer, with a relatively high activity at a relatively low, non-toxic dose.
    Type: Grant
    Filed: February 28, 2014
    Date of Patent: June 19, 2018
    Assignee: IMMUNOGEN, INC.
    Inventor: Wayne C. Widdison